Kamada (KMDA) Depreciation & Amortization (CF) (2012 - 2026)
Kamada (KMDA) posted quarterly Depreciation & Amortization (CF) of $3.9 million for Q1 2026, up 6.65% year-on-year from $3.6 million in Q1 2025, and up 1.32% on a QoQ basis from $3.8 million in Q4 2025.
Kamada (KMDA) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Depreciation & Amortization (CF) for 15 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 6.65% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.2 million (up 6.88% YoY) and the FY2025 annual result came in at $14.9 million, up 8.04% from the prior year.
- Depreciation & Amortization (CF) rose to $3.9 million in Q1 2026 per KMDA's latest filing, from $3.8 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for KMDA reached as high as $4.1 million in Q4 2024 and fell as low as $3012.0 in Q4 2022.
- A 5-year average of $2.8 million and a median of $3.2 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- The largest YoY upside for Depreciation & Amortization (CF) was 106407.3% in 2023 against a maximum downside of 99.9% in 2023.
- Year by year, Depreciation & Amortization (CF) stood at $3012.0 in 2022, then jumped by 106407.3% to $3.2 million in 2023, then climbed by 27.81% to $4.1 million in 2024, then slipped by 7.29% to $3.8 million in 2025, then increased by 1.32% to $3.9 million in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $3.9 million, $3.8 million, and $3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 3.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.85 Mn |
| Mar 31, 2026 | 3.85 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 3.76 Mn |
| Sep 30, 2025 | 3.76 Mn |
| Jun 30, 2025 | 3.75 Mn |
| Jun 30, 2025 | 3.75 Mn |
| Mar 31, 2025 | 3.61 Mn |
| Mar 31, 2025 | 3.61 Mn |
| Dec 31, 2024 | 4.10 Mn |
| Dec 31, 2024 | 4.10 Mn |
| Sep 30, 2024 | 3.24 Mn |
| Sep 30, 2024 | 3.24 Mn |
| Jun 30, 2024 | 3.23 Mn |
| Jun 30, 2024 | 3.23 Mn |
| Mar 31, 2024 | 3.24 Mn |
| Mar 31, 2024 | 3.24 Mn |
| Dec 31, 2023 | 3.21 Mn |
| Dec 31, 2023 | 3.21 Mn |